Marc Grasso
2019
In 2019, Marc Grasso earned a total compensation of $2.1M as Chief Financial Officer and Chief Business Officer at Kura Oncology, a 42% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $152,929 |
|---|---|
| Option Awards | $1,481,424 |
| Salary | $387,750 |
| Other | $90,179 |
| Total | $2,112,282 |
Grasso received $1.5M in option awards, accounting for 70% of the total pay in 2019.
Grasso also received $152.9K in non-equity incentive plan, $387.8K in salary and $90.2K in other compensation.
Rankings
In 2019, Marc Grasso's compensation ranked 5,652nd out of 13,971 executives tracked by ExecPay. In other words, Grasso earned more than 59.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,652 out of 13,971 | 60th |
Division Manufacturing | 2,114 out of 5,701 | 63rd |
Major group Chemicals And Allied Products | 757 out of 2,200 | 66th |
Industry group Drugs | 635 out of 1,886 | 66th |
Industry Pharmaceutical Preparations | 466 out of 1,398 | 67th |
Source: SEC filing on April 28, 2020.
Grasso's colleagues
We found five more compensation records of executives who worked with Marc Grasso at Kura Oncology in 2019.